Search Results

Saladax Biomedical, Inc. is pleased to announce that Health Canada has approved Saladax’s 5-Fluorouracil Assay for sale in Canada in a rapid six days.

Skye Bioscience, Inc. has treated the first patient in its Phase 2 clinical trial evaluating SBI-100 Ophthalmic Emulsion’s (“OE”) ability to lower intraocular pressure (“IOP”), safety and relevant biomarkers, in patients with primary open-angle glaucoma (“POAG”) or ocular hypertension (“OHT”).

Saladax Biomedical, Inc. is pleased to announce that it has acquired a patent portfolio for antipsychotic drug testing from Janssen Pharmaceutica NV.

Saladax Biomedical, Inc. (Saladax) is pleased to announce the signing of a global distribution agreement with Beckman Coulter, Inc. to distribute the MyCare™ Psychiatry Laboratory Assays. The MyCare™ Psychiatry Laboratory Assays measure drug levels of the antipsychotic drugs prescribed to treat patients with serious mental illness (SMI), such as such as Schizophrenia and Bipolar Disorder.

Clearside Biomedical, Inc. announced that multiple oral presentations were delivered at the Clinical Trials at the Summit Meeting on June 8, 2024 in Park City, Utah.

Lifecore Biomedical, Inc. announced it has reached a cooperation agreement with 22NW, LP, which provides for the addition of Humberto Antunes, Jason Aryeh, Paul Johnson and Matthew Korenberg to the Board of Directors of the Company effective immediately following the 2023 Annual Meeting of Stockholders.